New pain combo could cut opioid use after cancer surgery
NCT ID NCT07263165
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding dexmedetomidine to the standard numbing drug bupivacaine in a specific nerve block can reduce opioid painkiller use and pain intensity after upper abdominal cancer surgery. About 54 adults aged 18-70 scheduled for surgeries like gastrectomy or hepatectomy will be randomly assigned to receive either the combination or bupivacaine alone. The main goal is to see if the combo lowers total opioid consumption in the first 24 hours after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dexmedetomidine added to bupivacaine
- What this could lead to
- If it works, this could offer better pain control and less reliance on opioids after upper abdominal cancer surgery.
- What could go wrong
- This is a small, early-phase trial with only 54 participants, so results may not apply broadly. The added drug could also cause side effects like low blood pressure or slow heart rate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID CONSUMPTION, POSTOPERATIVE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New Non-Addictive pain drug could curb opioid dependence after surgery
- New nerve block technique aims to slash opioid use after breast reduction
- Ear zaps may cut opioid need after surgery
- New drug could slash opioid use after kidney stone surgery
- Two-minute video may slash opioid use after hernia surgery
- New pain block may cut opioid need after chest surgery